Sugi Predict

Sugi Predict / Compounds / SCHEMBL3168587

SCHEMBL3168587

SCHEMBL3168587

CN(Cc1ccc(F)cc1)C(=O)C(N)c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.74
▸ KMT2A Q03164 4/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ HPGD P15428 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TACR1 P25103 1/20 0.47
▸ RIPK1 Q13546 1/20 0.47
▸ SCN5A Q14524 1/20 0.46
▸ SCN9A Q15858 1/20 0.46
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ EPHX1 P07099 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4933726 1.00 TDP1 (0.74) TDP1KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL3239776 0.99 TDP1 (0.72) TDP1KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL3239786 0.99 TDP1 (0.72) TDP1KMT2AMEN1HPGDALDH1A1
SCHEMBL4204369 0.90 HPGD (0.59) TDP1KMT2AMEN1HPGDALDH1A1
SCHEMBL4192663 0.90 HPGD (0.59) TDP1KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL4208519 0.88 HPGD (0.58) TDP1KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL27601234 0.88 HPGD (0.58) TDP1KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL4198786 0.87 HPGD (0.56) TDP1KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL4203336 0.87 HPGD (0.56) TDP1KMT2AMEN1HPGDALDH1A1
Hydrochloric Acid SCHEMBL27583752 0.87 HPGD (0.56) TDP1KMT2AMEN1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008072056-A1 USE OF MTP INHIBITORS FOR THE TREATMENT OF OBESITY USING LOW DOSES AND DOSE-ESCALATION PFIZER LIMITED (GB) 2008-06-19 — — WO claimed
WO-2008072061-A1 METHOD OF TREATMENT OF OBESITY WITH AN MTP INHIBITOR IN CONJUNCTION WITH AN INCREASED-FAT DIET PFIZER PRODUCTS INC. (US) 2008-06-19 — — WO claimed
EP-1890767-A2 COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS Pfizer Products Inc. (US) 2008-02-27 — — EP claimed
WO-2006129193-A2 COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS PFIZER PRODUCTS INC. (US) 2006-12-07 — — WO claimed
US-20060270655-A1 Combination therapy for treating obesity or maintaining weight loss SWICK ANDREW G 2006-11-30 — — US claimed
US-20100113422-A1 Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists ANDREWS MARK 2010-05-06 — — US disclosed
US-20100008933-A1 Methods For Treating Obesity By Administering A TRKB Antagonist RINAT NEUROSCIENCE CORP. 2010-01-14 — — US disclosed
EP-2139896-A1 PYRIMIDO [4, 5-D]AZEPINE DERIVATIVES AS 5-HT2C AGONISTS Pfizer Limited (GB) 2010-01-06 — — EP disclosed
US-7618996-B2 Diaryl ether derivatives and uses thereof PFIZER INC. (US) 2009-11-17 — — US disclosed
US-7615651-B2 Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof PFIZER INC. (US) 2009-11-10 — — US disclosed
EP-2084127-A1 DIARYL, DIPYRIDINYL AND ARYL-PYRIDINYL DERIVATIVES AND USES THEREOF Pfizer Products Inc. (US) 2009-08-05 — — EP disclosed
EP-2078729-A1 PPY agonists and uses thereof Pfizer Products Inc. (US) 2009-07-15 — — EP disclosed
WO-2007088479-A1 METHODS FOR TREATING OBESITY BY ADMINISTERING A TRKB ANTAGONIST RINAT NEUROSCIENCE CORP. (US) 2007-08-09 — — WO disclosed
WO-2007085887-A1 PYY AGONISTS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2007-08-02 — — WO disclosed
WO-2007079317-A2 USE OF SEDATIVE HYPNOTICS FOR TREATING OBESITY OR MAINTAINING WEIGHT LOSS NEUROCRINE BIOSCIENCES, INC. (US) 2007-07-12 — — WO disclosed
CN-1914195-A Substituted quinoline compounds PFIZER PROD INC (US) 2007-02-14 — — CN disclosed
WO-2006129193-A2 COMBINATION OF A CANNABINOID-1- RECEPTOR-ANTAGONIST AND A MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR FOR TREATING OBESITY OR MAINATAINING WEIGHT LOSS PFIZER PRODUCTS INC. (US) 2006-12-07 — — WO disclosed
US-20060270655-A1 Combination therapy for treating obesity or maintaining weight loss SWICK ANDREW G 2006-11-30 — — US disclosed
US-20060178501-A1 PYY agonists and use thereof PFIZER INC 2006-08-10 — — US disclosed
WO-2006082517-A1 PYY AGONISTS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2006-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178501-A1 PYY agonists and use thereof NPY1R, NPY4R, NPY2R TDP1 3234/4885KMT2A 3642/4885MEN1 1941/4885
US-20100113422-A1 Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists HTR2C, HTR2A, HTR5A TDP1 3361/4885KMT2A 1526/4885MEN1 1573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.